Search - tctmd.com

Displaying 1 - 20 of 96

Sort: Relevancy | Date

News Industry News

The Lancet Publishes Twelve-Month Results for DESSOLVE III Highlighting MiStent® Performance in All-Comers Randomized Trial

December 06, 2017

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for November 2017

Shelley Wood

November 29, 2017

News Opinion Editor's Corner TCT 2017

My Takeaways From TCT 2017: Show Up, Keep It Civil, and Bring Your Best Self

Shelley Wood

November 22, 2017

News Daily News

Positionable Shields Slash Radiation Exposure to Cath Lab Staff by Two-Thirds

L.A. McKeown

November 08, 2017

Presentation TCT 2017

ABSORB II 4-Year, ABSORB III 3-Year, ABSORB IV 30-Day: Appreciation and Critique

Presenter: Martin B. Leon, Marco Valgimigli, Giulio G. Stefanini

November 01, 2017

Presentation TCT 2017

ABSORB II 4-Year, ABSORB III 3-Year, ABSORB IV 30-Day: Highlights Summary

Presenter: Martin B. Leon, Marco Valgimigli, Gregg W. Stone

November 01, 2017

Presentation TCT 2017

Bioresorbable Scaffolds and Stents: From PROSPECT-ABSORB to PREVENT (With Case Examples)

Presenter: Gregg W. Stone, Peter H. Stone, Jung-Min Ahn

November 01, 2017

Presentation TCT 2017

Do Some, All, or None of the Outcomes With the First Generation Absorb Scaffold Imply a Class Effect for All BRS? Educated Insights

Presenter: Bernard R. Chevalier, Corrado Tamburino, Yoshinobu Onuma

October 31, 2017

Presentation TCT 2017

Debate: With Improved Technology and Optimal Technique ABSORB Will Become a Widely Used Device

Presenter: Stephen G. Ellis, Takeshi Kimura, Hiram G. Bezerra

October 31, 2017

Presentation TCT 2017

Debate: ABSORB Is Likely Finished - The Limitation of the Technology Can Not Be Overcome

Presenter: Stephen G. Ellis, Takeshi Kimura, Robert A. Byrne

October 31, 2017

Presentation TCT 2017

The Potential For BRS: What Weve Learned From Pushing The Envelope

Presenter: Stephen G. Ellis, Takeshi Kimura, Corrado Tamburino

October 31, 2017

Presentation TCT 2017

Registry Update: ABSORB SCAAR

Presenter: Stephen G. Ellis, Takeshi Kimura, Stefan K. James

October 31, 2017

Presentation TCT 2017

Registry Update: BVS STEMI STRATEGY

Presenter: Stephen G. Ellis, Takeshi Kimura, Alfonso Ielasi

October 31, 2017

Presentation TCT 2017

Registry Update: IT-DISAPPEARS

Presenter: Stephen G. Ellis, Takeshi Kimura, Francesco Bedogni

October 31, 2017

Presentation TCT 2017

Registry Update: FRANCE ABSORB

Presenter: Stephen G. Ellis, Takeshi Kimura, Didier Carrié

October 31, 2017

Presentation TCT 2017

Registry Update: GABI-R

Presenter: Stephen G. Ellis, Takeshi Kimura, Holger M. Nef

October 31, 2017

Presentation TCT 2017

Registry Update: ABSORB UK

Presenter: Stephen G. Ellis, Takeshi Kimura, Mark A. de Belder

October 31, 2017

Presentation TCT 2017

Registry Update: ABSORB Extend At 3 Years

Presenter: Stephen G. Ellis, Takeshi Kimura, Antonio L. Bartorelli

October 31, 2017

Presentation TCT 2017

What Is the Optimal DAPT Duration With ABSORB? Results From a Comprehensive Meta-Analysis

Presenter: Azeem Latib, Gregg W. Stone

October 31, 2017

Presentation TCT 2017

ABSORB IV 30-Day Results: Is Improved Technique Reflected in Superior Early Outcomes?

Presenter: Azeem Latib, Dean J. Kereiakes

October 31, 2017

Advertisement

The Lancet Publishes Twelve-Month Results for DESSOLVE III Highlighting MiStent® Performance in All-Comers Randomized Trial

TCTMD’s Top 10 Most Popular Stories for November 2017

My Takeaways From TCT 2017: Show Up, Keep It Civil, and Bring Your Best Self

Positionable Shields Slash Radiation Exposure to Cath Lab Staff by Two-Thirds

ABSORB II 4-Year, ABSORB III 3-Year, ABSORB IV 30-Day: Appreciation and Critique

ABSORB II 4-Year, ABSORB III 3-Year, ABSORB IV 30-Day: Highlights Summary

Bioresorbable Scaffolds and Stents: From PROSPECT-ABSORB to PREVENT (With Case Examples)

Do Some, All, or None of the Outcomes With the First Generation Absorb Scaffold Imply a Class Effect for All BRS? Educated Insights

Debate: With Improved Technology and Optimal Technique ABSORB Will Become a Widely Used Device

Debate: ABSORB Is Likely Finished - The Limitation of the Technology Can Not Be Overcome

The Potential For BRS: What Weve Learned From Pushing The Envelope

Registry Update: ABSORB SCAAR

Registry Update: BVS STEMI STRATEGY

Registry Update: IT-DISAPPEARS

Registry Update: FRANCE ABSORB

Registry Update: GABI-R

Registry Update: ABSORB UK

Registry Update: ABSORB Extend At 3 Years

What Is the Optimal DAPT Duration With ABSORB? Results From a Comprehensive Meta-Analysis

ABSORB IV 30-Day Results: Is Improved Technique Reflected in Superior Early Outcomes?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content